1. Home
  2. CIX vs DMAC Comparison

CIX vs DMAC Comparison

Compare CIX & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CompX International Inc.

CIX

CompX International Inc.

N/A

Current Price

$21.17

Market Cap

296.5M

ML Signal

N/A

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$9.38

Market Cap

457.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIX
DMAC
Founded
1993
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
296.5M
457.2M
IPO Year
1998
N/A

Fundamental Metrics

Financial Performance
Metric
CIX
DMAC
Price
$21.17
$9.38
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$15.50
AVG Volume (30 Days)
11.7K
581.8K
Earning Date
11-05-2025
11-12-2025
Dividend Yield
10.41%
N/A
EPS Growth
2.86
N/A
EPS
1.57
N/A
Revenue
$159,004,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.92
N/A
Revenue Growth
5.52
N/A
52 Week Low
$17.89
$3.19
52 Week High
$32.30
$10.42

Technical Indicators

Market Signals
Indicator
CIX
DMAC
Relative Strength Index (RSI) 48.76 69.32
Support Level $20.29 $7.76
Resistance Level $22.05 $10.42
Average True Range (ATR) 0.53 0.71
MACD -0.05 0.09
Stochastic Oscillator 61.22 64.37

Price Performance

Historical Comparison
CIX
DMAC

About CIX CompX International Inc.

Compx International Inc is a manufacturer of security products. Its security products are used in recreational transportation, postal, office & institutional furniture, cabinetry, tool storage, healthcare, and a variety of other industries. Also, it is engaged in the manufacturing of stainless steel exhaust systems, gauges, throttle controls, and trim tabs for the recreational marine industry. The company's operating segment includes Security Products and Marine Components. The company generates maximum revenue from the Security Products segment, which manufactures mechanical and electrical cabinet locks and other locking mechanisms. Its geographical segments are the United States, Canada, Mexico, and others, of which the United States accounts for the vast majority of revenue.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: